STRO-001 has the potential to help patients with diverse blood cancers, Dr Greenberger noted. It is the first ADC for which the LLS has offered funding through its Therapy Acceleration Program (TAP).

The company’s preclinical cell line and xenograft research suggested that STRO-001 is highly specific to CD74 and confirmed the high expression levels of CD74 on myeloma and lymphoma tumor cells.

The clinical trial team started enrolling patients with multiple myeloma, diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma in the phase 1 safety and tolerability study in April 2018, at the City of Hope Comprehensive Cancer Center in Duarte, California; the Medical College of Wisconsin in Milwaukee; Texas Oncology in Austin; the Rocky Mountain Cancer Centers in Aurora, Colorado; and at Virginia Cancer Specialists in Fairfax.

The hope is that next-generation ADCs will limit off-tumor-target activity and its resulting side effects.

STRO-001 is just one of many ADCs under development for the treatment of B-cell malignancies. Dozens of other phase 1 and phase 2 clinical trials are underway, testing ADC monotherapies and combination regimens of ADCs plus immune checkpoint inhibitors.2

Related Articles

The LLS has invested $150 million in its TAP since it was started in 2007 to hasten the development of promising treatments, Dr Greenberger said. The program has been highly effective in accelerating new blood cancer therapies to patients, including CD19-targeting chimeric antigen receptor T-cell (CAR-T) immunotherapy for several types of large B-cell lymphomas (YescartaTM) and a liposomal formulation of cytotoxic drugs for AML (VyxeosTM), both approved by the US Food and Drug Administration in 2017. STRO-001 is the first ADC in LLS’s TAP portfolio.

References

  1. Corraliza-Gorjón I, Somovilla-Crespo B, Santamaria S, Garcia-Sanz JA, Kremer L. New strategies using antibody combinations to increase cancer treatment effectiveness. Front Immunol. 2017;8:1804.
  2. Herrera AF, Molina A. Investigational antibody–drug conjugates for treatment of B-lineage malignancies. Clin Lymphoma Myeloma Leuk. 2018;18(7):452-468.